INCRETIN-BASED THERAPIES FOR OBESITY MANAGEMENT: THE IMPACT OF PATIENT EDUCATION AND LIFESTYLE MODIFICATION ON LONG-TERM TREATMENT OUTCOMES
Abstract
Obesity represents one of the most pressing global health challenges, driven by complex biological, behavioral, and environmental factors. Incretin-based pharmacotherapies, such as GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists, have redefined the clinical approach to obesity management by enabling substantial and sustained weight reduction. However, long-term treatment success extends beyond pharmacological efficacy alone. This review examines the role of patient education and lifestyle modification as critical determinants of adherence, behavioral change, and sustainability of weight loss during incretin therapy. Integrating pharmacotherapy with structured education, digital coaching, and telehealth-based interventions enhances motivation, reduces treatment fatigue, and promotes lasting metabolic improvement. The interdisciplinary model proposed in this study positions patient empowerment and health literacy as key drivers of therapeutic success. By combining medical innovation with behavioral and social approaches, incretin therapy can evolve into a cornerstone of holistic, technology-supported chronic obesity management.
References
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., Kushner, R. F., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., … Gabbay, R. A. (2024). 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes–2024. Diabetes Care, 47(Supplement_1), S145–S157. https://doi.org/10.2337/dc24-S008
Aronne, L. J., Horn, D. B., Le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. P. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine, 393(1), 26–36. https://doi.org/10.1056/NEJMoa2416394
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., Jouravskaya, I., Murphy, M. A., SURMOUNT-4 Investigators, Fretes, J. O., Coronel, M. J., Gutnisky, L. L., Frechtel, G. D., Gelersztein, E., Aizenberg, D., … Nardandrea, J. P. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38. https://doi.org/10.1001/jama.2023.24945
Berg, S., Stickle, H., Rose, S. J., & Nemec, E. C. (2025). Discontinuing glucagon‐like peptide‐1 receptor agonists and body habitus: A systematic review and meta‐analysis. Obesity Reviews, 26(8), e13929. https://doi.org/10.1111/obr.13929
Boer, G. A., Hay, D. L., & Tups, A. (2023). Obesity pharmacotherapy: Incretin action in the central nervous system. Trends in Pharmacological Sciences, 44(1), 50–63. https://doi.org/10.1016/j.tips.2022.11.001
Brandt, S. J., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Stemmer, K. (2018). Peptide‐based multi‐agonists: A new paradigm in metabolic pharmacology. Journal of Internal Medicine, 284(6), 581–602. https://doi.org/10.1111/joim.12837
Cai, W., Zhang, R., Yao, Y., Wu, Q., & Zhang, J. (2024). Tirzepatide as a novel effective and safe strategy for treating obesity: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Public Health, 12, 1277113. https://doi.org/10.3389/fpubh.2024.1277113
Campbell, J. E., Müller, T. D., Finan, B., DiMarchi, R. D., Tschöp, M. H., & D’Alessio, D. A. (2023). GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—Chemistry, physiology, and clinical applications. Cell Metabolism, 35(9), 1519–1529. https://doi.org/10.1016/j.cmet.2023.07.010
Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S., & Giorgino, F. (2024). Incretin-based therapies for the treatment of obesity-related diseases. Npj Metabolic Health and Disease, 2(1), 31. https://doi.org/10.1038/s44324-024-00030-5
Chetty, A. K., Rafi, E., Bellini, N. J., Buchholz, N., & Isaacs, D. (2024). A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management. Endocrine Practice, 30(3), 292–303. https://doi.org/10.1016/j.eprac.2023.12.010
Emmerich, S., Fryar, C., Stierman, B., & Ogden, C. (2024). Obesity and Severe Obesity Prevalence in Adults: United States, August 2021–August 2023. National Center for Health Statistics (U.S.). https://doi.org/10.15620/cdc/159281
Espinosa, M. A., Rivera Gutierrez, R. D. J., Villamarin, J., & Acosta, A. (2025). Precision Medicine for Obesity Treatment. Journal of the Endocrine Society, 9(9), bvaf102. https://doi.org/10.1210/jendso/bvaf102
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016). American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity. Endocrine Practice, 22, 1–203. https://doi.org/10.4158/EP161365.GL
Ghusn, W., De La Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., Feris, F., Hurtado, M. D., & Acosta, A. (2022). Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Network Open, 5(9), e2231982. https://doi.org/10.1001/jamanetworkopen.2022.31982
Giordano, U., Kobiałka, J., & Pilch, J. (2023). Semaglutide as a chance for obesity treatment. Medical Research Journal, 8(3), 262–264. https://doi.org/10.5603/MRJ.a2023.0034
Iorga, R., Bacalbasa, N., Carsote, M., Bratu, O., Stanescu, A. M., Bungau, S., Pantis, C., & Diaconu, C. (2020). Metabolic and cardiovascular benefits of GLP‑1 agonists, besides the hypoglycemic effect (Review). Experimental and Therapeutic Medicine. https://doi.org/10.3892/etm.2020.8714
Irvin, L., Madden, L. A., Marshall, P., & Vince, R. V. (2023). Digital Health Solutions for Weight Loss and Obesity: A Narrative Review. Nutrients, 15(8), 1858. https://doi.org/10.3390/nu15081858
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
Kosiborod, M. N., Bhatta, M., Davies, M., Deanfield, J. E., Garvey, W. T., Khalid, U., Kushner, R., Rubino, D. M., Zeuthen, N., & Verma, S. (2023). Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes, Obesity and Metabolism, 25(2), 468–478. https://doi.org/10.1111/dom.14890
Kraschnewski, J. L., Kong, L., Bryce, C. L., Francis, E. B., Poger, J. M., Lehman, E. B., Helbling, S., Soleymani, T., Mancoll, R. E., Villalobos, V., & Yeh, H.-C. (2023). Intensive behavioral Therapy for weight loss in patients with, or At-Risk of, type 2 Diabetes: Results from the PaTH to health diabetes study. Preventive Medicine Reports, 31, 102099. https://doi.org/10.1016/j.pmedr.2022.102099
Kupila, S. K. E., Joki, A., Suojanen, L.-U., & Pietiläinen, K. H. (2023). Correction: The Effectiveness of eHealth Interventions for Weight Loss and Weight Loss Maintenance in Adults with Overweight or Obesity: A Systematic Review of Systematic Reviews. Current Obesity Reports, 12(4), 544–545. https://doi.org/10.1007/s13679-023-00530-3
Kyriakidou, A., Kyriazou, A. V., Koufakis, T., Vasilopoulos, Y., Grammatiki, M., Tsekmekidou, X., Avramidis, I., Baltagiannis, S., Goulis, D. G., Zebekakis, P., & Kotsa, K. (2022). Clinical and Genetic Predictors of Glycemic Control and Weight Loss Response to Liraglutide in Patients with Type 2 Diabetes. Journal of Personalized Medicine, 12(3), 424. https://doi.org/10.3390/jpm12030424
Lee, M., Lauren, B. N., Zhan, T., Choi, J., Klebanoff, M., Abu Dayyeh, B., Taveras, E. M., Corey, K., Kaplan, L., & Hur, C. (2020). The cost‐effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. Obesity Science & Practice, 6(2), 162–170. https://doi.org/10.1002/osp4.390
Look, M., Dunn, J. P., Kushner, R. F., Cao, D., Harris, C., Gibble, T. H., Stefanski, A., & Griffin, R. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 27(5), 2720–2729. https://doi.org/10.1111/dom.16275
Montan, P. D., Sourlas, A., Olivero, J., Silverio, D., Guzman, E., & Kosmas, C. E. (2019). Pharmacologic therapy of obesity: Mechanisms of action and cardiometabolic effects. Annals of Translational Medicine, 7(16), 393–393. https://doi.org/10.21037/atm.2019.07.27
Müller, T. D., Finan, B., Bloom, S. R., D’Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., … Tschöp, M. H. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. https://doi.org/10.1016/j.molmet.2019.09.010
Ng, M., Gakidou, E., Lo, J., Abate, Y. H., Abbafati, C., Abbas, N., Abbasian, M., Abd ElHafeez, S., Abdel-Rahman, W. M., Abd-Elsalam, S., Abdollahi, A., Abdoun, M., Abdulah, D. M., Abdulkader, R. S., Abdullahi, A., Abedi, A., Abeywickrama, H. M., Abie, A., Aboagye, R. G., … Vollset, S. E. (2025). Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: A forecasting study for the Global Burden of Disease Study 2021. The Lancet, 405(10481), 813–838. https://doi.org/10.1016/S0140-6736(25)00355-1
Qin, W., Yang, J., Deng, C., Ruan, Q., & Duan, K. (2024). Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year STEP 5 trial. Diabetes, Obesity and Metabolism, 26(3), 911–923. https://doi.org/10.1111/dom.15386
Rodriguez, P. J., Goodwin Cartwright, B. M., Gratzl, S., Brar, R., Baker, C., Gluckman, T. J., & Stucky, N. L. (2024). Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Internal Medicine, 184(9), 1056. https://doi.org/10.1001/jamainternmed.2024.2525
Ross, K. M., Carpenter, C. A., Arroyo, K. M., Shankar, M. N., Yi, F., Qiu, P., Anthony, L., Ruiz, J., & Perri, M. G. (2022). Impact of transition from face‐to‐face to telehealth on behavioral obesity treatment during the COVID‐19 pandemic. Obesity, 30(4), 858–863. https://doi.org/10.1002/oby.23383
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., STEP 4 Investigators, Friberg, M., Sjödin, A., Dicker, D., Segal, G., … Warren, M. L. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414. https://doi.org/10.1001/jama.2021.3224
Rubino, F., Puhl, R. M., Cummings, D. E., Eckel, R. H., Ryan, D. H., Mechanick, J. I., Nadglowski, J., Ramos Salas, X., Schauer, P. R., Twenefour, D., Apovian, C. M., Aronne, L. J., Batterham, R. L., Berthoud, H.-R., Boza, C., Busetto, L., Dicker, D., De Groot, M., Eisenberg, D., … Dixon, J. B. (2020). Joint international consensus statement for ending stigma of obesity. Nature Medicine, 26(4), 485–497. https://doi.org/10.1038/s41591-020-0803-x
Tronieri, J. S., Wadden, T. A., Walsh, O., Berkowitz, R. I., Alamuddin, N., & Chao, A. M. (2020). Measures of adherence as predictors of early and total weight loss with intensive behavioral therapy for obesity combined with liraglutide 3.0 mg. Behaviour Research and Therapy, 131, 103639. https://doi.org/10.1016/j.brat.2020.103639
Unick, J. L., Pellegrini, C. A., Dunsiger, S. I., Demos, K. E., Thomas, J. G., Bond, D. S., Lee, R. H., Webster, J., & Wing, R. R. (2024). An Adaptive Telephone Coaching Intervention for Patients in an Online Weight Loss Program: A Randomized Clinical Trial. JAMA Network Open, 7(6), e2414587. https://doi.org/10.1001/jamanetworkopen.2024.14587
Van Baak, M. A., & Mariman, E. C. M. (2025). Physiology of Weight Regain after Weight Loss: Latest Insights. Current Obesity Reports, 14(1), 28. https://doi.org/10.1007/s13679-025-00619-x
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., Wallenstein, S. O. R., Garvey, W. T., & STEP 3 Investigators. (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA, 325(14), 1403. https://doi.org/10.1001/jama.2021.1831
Wang, D., Benito, P. J., Rubio‐Arias, J. Á., Ramos‐Campo, D. J., & Rojo‐Tirado, M. A. (2024). Exploring factors of adherence to weight loss interventions in population with overweight/obesity: An umbrella review. Obesity Reviews, 25(9), e13783. https://doi.org/10.1111/obr.13783
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K., Kushner, R. F., & STEP 1 Study Group. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725
Copyright (c) 2025 Natalia Senatorska, Katarzyna Kleszczewska, Agnieszka Pruska, Julia Rarok, Daria Godlewska, Hanna Pietruszewska, Monika Banaszek, Agata Panfil, Julia Błocka, Agata Lurka
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
